Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Exact Sciences (EXAS) to $72 from $69 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results which showed early signs of improved commercial execution.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences: Strong Q1 Performance and Promising Prospects Justify Buy Rating
- Exact Sciences price target raised to $75 from $55 at Barclays
- Exact Sciences Reports Strong Q1 2025 Results
- Closing Bell Movers: Apple and Amazon slip after earnings
- Exact Sciences reports Q1 EPS (54c) vs (60c) last year